Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Aronson

Showing results (261-270 of 634) with videos related to

Pageof 64
Sort By:
Nature Medicine|January 3, 2001
Forbidden fruitJ K Aronson
British Journal of Clinical Pharmacology|January 1, 1978
Monitoring digoxin therapy: III. How useful are the nomograms?J K Aronson
BMJ (Clinical Research Ed.)|November 28, 2025
When I use a word . . . Hospitalists-advantages and disadvantagesJeffrey K Aronson
Biochemical Pharmacology|January 9, 1992
Potassium channels in nervous tissueJ K Aronson
BMJ (Clinical Research Ed.)|June 23, 2007
Glomerular filtration rate: eGFR in changing drug regimensJeffrey K Aronson
British Journal of Clinical Pharmacology|May 10, 2007
Drug therapy in kidney diseaseJeffrey K Aronson
BMJ (Clinical Research Ed.)|February 2, 2012
Surrogate end points: studying their benefits, taxonomy, and semanticsJeffrey K Aronson
British Journal of Clinical Pharmacology|December 7, 2011
David Grahame Grahame-Smith: clinical pharmacologist. 1933-2011Jeffrey K Aronson
BMJ (Clinical Research Ed.)|October 21, 2022
When I use a word . . . . Too much healthcare-BiomarkersJeffrey K Aronson
BMJ (Clinical Research Ed.)|September 23, 2022
When I use a word . . . . Too much healthcare-uncertainty, underconfidence, and masterly inactivityJeffrey K Aronson
Pageof 64

Showing results (261-270 of 634) with videos related to

Sort By:
Pageof 64
Nature Medicine|January 3, 2001
Forbidden fruitJ K Aronson
British Journal of Clinical Pharmacology|January 1, 1978
Monitoring digoxin therapy: III. How useful are the nomograms?J K Aronson
BMJ (Clinical Research Ed.)|November 28, 2025
When I use a word . . . Hospitalists-advantages and disadvantagesJeffrey K Aronson
Biochemical Pharmacology|January 9, 1992
Potassium channels in nervous tissueJ K Aronson
BMJ (Clinical Research Ed.)|June 23, 2007
Glomerular filtration rate: eGFR in changing drug regimensJeffrey K Aronson
British Journal of Clinical Pharmacology|May 10, 2007
Drug therapy in kidney diseaseJeffrey K Aronson
BMJ (Clinical Research Ed.)|February 2, 2012
Surrogate end points: studying their benefits, taxonomy, and semanticsJeffrey K Aronson
British Journal of Clinical Pharmacology|December 7, 2011
David Grahame Grahame-Smith: clinical pharmacologist. 1933-2011Jeffrey K Aronson
BMJ (Clinical Research Ed.)|October 21, 2022
When I use a word . . . . Too much healthcare-BiomarkersJeffrey K Aronson
BMJ (Clinical Research Ed.)|September 23, 2022
When I use a word . . . . Too much healthcare-uncertainty, underconfidence, and masterly inactivityJeffrey K Aronson
Pageof 64